Knight Cardiovascular Institute, Department of Medicine (D.L.P., A.M.F., S.R., P.B., J.M., N.J.A., S.F., N.P.), Oregon Health & Science University, Portland, OR.
Proteomics Shared Resource (P.A.W.), Oregon Health & Science University, Portland, OR.
Circ Res. 2020 Oct 23;127(10):1274-1287. doi: 10.1161/CIRCRESAHA.120.316526. Epub 2020 Aug 26.
Prospective cohort studies question the value of HDL-C (high-density lipoprotein cholesterol) for stroke risk prediction.
Investigate the relationship between long-term functional recovery and HDL proteome and function.
Changes in HDL protein composition and function (cholesterol efflux capacity) in patients after acute ischemic stroke at 2 time points (24 hours, 35 patients; 96 hours, 20 patients) and in 35 control subjects were measured. The recovery from stroke was assessed by 3 months, the National Institutes of Health Stroke Scale and modified Rankin scale scores. When compared with control subject after adjustments for sex and HDL-C levels, 12 proteins some of which participate in acute phase response and platelet activation (APMAP [adipocyte plasma membrane-associated protein], GPLD1 [phosphate inositol-glycan specific phospholipase D], APOE [apolipoprotein E], IHH [Indian hedgehog protein], ITIH4 [inter-alpha-trypsin inhibitor chain H4], SAA2 [serum amyloid A2], APOA4 [apolipoprotein A-IV], CLU [clusterin], ANTRX2 [anthrax toxin receptor 2], PON1 [serum paraoxonase/arylesterase], SERPINA1 [alpha-1-antitrypsin], and APOF [apolipoprotein F]) were significantly (adjusted <0.05) altered in stroke HDL at 96 hours. The first 8 of these proteins were also significantly altered at 24 hours. Consistent with inflammatory remodeling, cholesterol efflux capacity was reduced by 32% (<0.001) at both time points. Baseline stroke severity adjusted regression model showed that changes within 96-hour poststroke in APOF, APOL1, APMAP, APOC4 (apolipoprotein C4), APOM (apolipoprotein M), PCYOX1 (prenylcysteine oxidase 1), PON1, and APOE correlate with stroke recovery scores (=0.38-0.73, adjusted <0.05). APOF (=0.73) and APOL1 (=0.60) continued to significantly correlate with recovery scores after accounting for tPA (tissue-type plasminogen activator) treatment.
Changes in HDL proteins during early acute phase of stroke associate with recovery. Monitoring HDL proteins may provide clinical biomarkers that inform on stroke recuperation.
前瞻性队列研究对高密度脂蛋白胆固醇(HDL-C)在卒中风险预测中的价值提出了质疑。
研究长期功能恢复与 HDL 蛋白质组和功能之间的关系。
分别在急性缺血性卒中后 24 小时(35 例患者)和 96 小时(20 例患者)及 35 例对照者中检测 2 个时间点患者的 HDL 蛋白组成和功能(胆固醇外排能力)的变化。采用 3 个月的国立卫生研究院卒中量表和改良 Rankin 量表评分评估卒中恢复情况。与调整性别和 HDL-C 水平后的对照者相比,12 种蛋白(其中一些参与急性期反应和血小板激活)在 96 小时时发生变化(APMAP[脂肪细胞膜相关蛋白]、GPLD1[磷酸肌醇聚糖特异性磷脂酶 D]、APOE[载脂蛋白 E]、IHH[印度 hedgehog 蛋白]、ITIH4[α-1-抗胰蛋白酶抑制剂链 H4]、SAA2[血清淀粉样 A2]、APOA4[载脂蛋白 A-IV]、CLU[聚类素]、ANTRX2[炭疽毒素受体 2]、PON1[血清对氧磷酶/芳基酯酶]、SERPINA1[α-1-抗胰蛋白酶]和 APOF[载脂蛋白 F])。这 8 种蛋白中的前 8 种也在 24 小时时发生了显著变化。与炎症重塑一致,胆固醇外排能力在两个时间点均降低了 32%(<0.001)。在调整基线卒中严重程度的回归模型中,卒中后 96 小时内,APOF、APOL1、APMAP、APOC4(载脂蛋白 C4)、APOM(载脂蛋白 M)、PCYOX1(prenylcysteine oxidase 1)、PON1 和 APOE 的变化与卒中恢复评分相关(=0.38-0.73,调整后<0.05)。APOF(=0.73)和 APOL1(=0.60)在考虑 tPA(组织型纤溶酶原激活物)治疗后,与恢复评分仍显著相关。
卒中急性期 HDL 蛋白的变化与恢复相关。监测 HDL 蛋白可能提供临床生物标志物,以告知卒中恢复情况。